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doi:10.1016/j.pedneo.2011.06.006Background: Clinical features and treatment responses in pediatric patients with eosinophilic
gastroenteritis are rarely reported. This study aimed to evaluate the clinical manifestations
and outcome of eosinophilic gastroenteritis in children of Asian background.
Methods: Between 1997 and 2009, 14 Taiwanese patients (nine boys and five girls), with
median age of 8.3 years (range, 1.4e14.3 years), were diagnosed with eosinophilic gastroen-
teritis. The diagnosis was confirmed by the presence of gastrointestinal symptoms, peripheral
eosinophilia, and a histology-proved biopsy. The clinical data and responses to medical treat-
ment were analyzed.
Results: Initial symptoms included abdominal pain (43%), anemia (36%), hypoalbuminemia (14%),
recurrent vomiting (7%), bloody stool (7%), and growth failure (7%). Peripheral eosinophilia was
present in 10 patients (71.4%) and positive stool occult blood in seven patients (50%). Endoscopic
examination revealed ulcer disease in four patients (28.6%). The treatment included steroid
alone, montelukast alone, steroid þmontelukast, and steroid þmontelukast þ ketotifen.
Among the patients treated with steroid, two (two of nine, 22%) had successfully tapered
off steroid without recurring symptoms. Three patients (three of nine, 33%) had relapses
after discontinuing steroid, three (three of nine, 33%) still required low-dose steroid, and
one lost to follow-up. There was no relapse in the four patients treated with montelukast
alone.of Pediatrics, National Taiwan University Children’s Hospital and National Taiwan University College
Road, Taipei, Taiwan.
.tw (H.-L. Chen).
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Pediatric eosinophilic gastroenteritis 273Conclusions: A high percentage of patients presented with gross or occult gastrointestinal
bleeding with or without abdominal pain. Endoscopic biopsy is necessary for diagnosis.
Steroid was the mainstay treatment for active diseases; montelukast was also effective for
the disease or as a maintenance therapy in this study.
Copyright ª 2011, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Eosinophilic gastroenteritis is characterized by eosinophil
infiltrations of the gastrointestinal tract, resulting in vari-
able symptoms.1 First described in 1937 by Kaijser,2 its
actual incidence is difficult to estimate. Klein et al3
reported the concept of classification by the different
layers involved: predominant mucosal, muscle layer, and
subserosal diseases. The most common affected sites are
the stomach and proximal intestine,4 although it can affect
any area of the gastrointestinal tract from esophagus to
rectum. The pathogenesis is not fully understood, and it is
still considered as an allergic mechanism.5 Clinical mani-
festations depend on the involved sites and layers. Patients
with eosinophilic gastroenteritis may present with abdom-
inal pain, nausea, vomiting, diarrhea, weight loss, gastro-
intestinal bleeding, intestinal malabsorption, or ascites.6,7
Eosinophilic gastroenteritis can be observed in any age
group, but reports in the pediatric group are rare.8 Other
causes of intestinal eosinophilia, including parasite
infection,9e11 inflammatory bowel disease,12 collagen
vascular disease,13 or malignancy, should be ruled out
before the diagnosis of eosinophilic gastroenteritis is
confirmed. Peripheral blood eosinophilia and food allergy
are not always necessary for the diagnosis,4,14 but they may
be the initial clue. Elevated Immunoglobulin E (IgE) can be
observed in some cases. The presence of eosinophilic
infiltration in biopsy specimen is supportive of eosinophilic
gastroenteritis. Previous studies showed limited data in
pediatric group, and most of the patients in those studies
were treated with corticosteroid.8 Some case reports
showed effective results of montelukast therapy, but long-
term prognosis was lacking.15,16 Eosinophilic gastroenteritis
in Asian children has not been reported. In our study, we
reviewed our experience in the past 12 years of eosinophilic
gastroenteritis with regard to clinical course, laboratory
features, treatment response, and prognosis.
2. Materials and Methods
Between 1997 and 2009, 14 patients (nine boys and five girls
from 12 families, aged 1.4e14.3 years) were diagnosed as
having eosinophilic gastroenteritis in the Department of
Pediatrics, National Taiwan University Hospital. The median
age at symptom onset was 7.5 years (0.3e14 years). The ages
of diagnosis were all greater than 1 year to distinguish the
diagnosis from cow’s milk protein allergy in infancy. We set
the criteria of diagnosis as follows: (1) the presence of
gastrointestinal symptoms; (2) an increased eosinophilic
infiltration in the gastrointestinal tract on a biopsy spec-
imen; and (3) peripheral eosinophilia (>600 cells/mL).
Patients were diagnosed as having “definite eosinophilicgastroenteritis” if they met Criteria (1) and (2) and other
patients as having “probable eosinophilic gastroenteritis”
when Criteria (1) and (3) were met. The exclusion criteria
included inflammatory bowel disease, parasite infection,
neoplasm, collagen vascular disease, and Churg-Strauss
syndrome. The initial manifestations; the onset and dura-
tion of symptoms before diagnosis; history of allergy; family
history of allergy (defined as asthma, atopy, and drug allergy
or food intolerance); endoscopic findings; pathological
results; and duration of follow-up were analyzed. Patients
were defined as steroid dependent when they had partial or
complete response to steroiduse, and the symptomscouldbe
controlled only by continuous use of corticosteroid. The
laboratory data included peripheral eosinophil count,
erythrocyte sedimentation rate, serum IgE concentrations,
and serum albumin. Increased eosinophilic infiltration in the
gastrointestinal tract was defined as more than 20 eosino-
phils per one high-power field under microscopic examina-
tion, which was interpreted by a single experienced
pathologist blinded to the previous investigations. Seven
patients had received allergen-specific IgE testing (Immu-
noCap; Pharmacia Diagnostics AB, Uppsala, Sweden). The
treatment and prognosis, including episodes of relapse and
the duration of steroid tapering, were analyzed.
2.1. Statistical analysis
The STATA software package (StataCorp LP, College Station,
TX, USA) was used for statistical analysis. Mann-Whitney U
test was used for continuous variables. Statistical signifi-
cance was assumed with p< 0.05.
3. Results
3.1. Clinical and laboratory results
Fourteen patients were diagnosed with eosinophilic gastro-
enteritis according to our criteria. The median age at time of
diagnosis was 8.3 years (range, 1.4e14.3 years). The median
duration from onset of symptoms to diagnosis was 3 months
(range, 0.2e36 months). The initial symptoms included
abdominal pain, anemia, hypoalbuminemia, recurrent vomit-
ing, and bloody stool. Table 1 reveals the general character-
istics and laboratory results of our patients. Half of the
patients (7of14)presentedwithgrossorocculthematochezia,
and a high percentage of patients had significant anemia with
hemoglobin (Hb)< 8 mg/dL (5 of 14, 36%). Peripheral eosino-
philia (>600 cells/mL) was present in 10 patients (71.4%) at
initial diagnosis, and the median absolute eosinophil count in
serum was 1011 counts/mL (range, 167e15,605).
History of atopy was noticed in four (4 of 14, 28.6%)
patients, including asthma and allergic rhinitis. One-third
Table 1 Clinical features and laboratory findings of patients with eosinophilic gastroenteritis.
No. Sex Age at
diagnosis
(y)
Duration of
symptom before
diagnosis (mo)
Initial symptoms
and signs
Serum eosinophil
count (cells/mL)
Albumin
(g/dL)
Stool
OB
IgE
(IU/mL)
Allergen-specific
IgE testing
1 F 8.6 6 Abdominal pain 15,605 4.4  2190 
2 M 14 24 Abdominal pain 14,650 3.2 þ 1285 ND
3 M 14.3 3 Abdominal pain 1541 5 ND ND Mite
4 F 14.1 1 Abdominal pain 737 5 ND 94.8 
5 F 13 0.75 Abdominal pain 601 ND ND 48.9 Mite
6 F 6 36 Anemia,
hypoalbuminemia
503 2.4 þ ND ND
7 M 11.1 14 Hypoalbuminemia 462 2.2  ND ND
8 M 1.5 3 Anemia 1365 1.91 þ ND ND
9 M 1.4 14 Chronic vomiting 360 4.8  ND 
10 M 6 1 Anemia 3777 ND þ 3947 Mite, multiple food
11 M 8 24 Anemia 1519 3 þ 1603 Multiple food
12 M 7 0.75 Bloody stool 167 ND þ 3.81 
13 M 10.5 0.25 Abdominal pain 968 4.7  487 ND
14 F 3.4 0.2 Anemia 1054 5 þ 751 Multiple food
FZ female; MZmale; NDZ not done; OB Z occult blood.
Table 2 Clinical manifestation and endoscopic finding of
14 patients.
n (%)
Symptoms and signs
Abdominal pain 6 (43)
Anemia (Hb< 8.0 g/dL) 5 (36)
Hypoalbuminemia (<3.5 g/dL) 2 (14)
Recurrent vomiting 1 (7)
Bloody stool 1 (7)
Growth failure (<3rd percentile) 1 (7)
Endoscopic finding
Ulcer disease (nZ 4, 28.6%)
Gastric ulcer 1
Duodenal ulcer 1
Ileal ulcer 1
Colon ulcer 1
Nonulcer disease (nZ 9, 64.3%)
Gastritis 9
Esophagitis 1
Duodenitis 4
Negative finding (nZ 1, 7.1%) 1
Data are presented as n or n (%).
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specific IgE testing were allergic to multiple foods, and two-
thirds (six of nine, 66.7%) of the patients had elevated
levels of serum IgE. The median level of serum IgE was
1285 IU/mL (range, 3.81e3947 IU/mL). Forty-five percent
of the patients had serum albumin levels less than 3.5 g/dL.
The median level of serum albumin was 4.4 g/dL (range,
1.9e5.0 g/dL). Elevated erythrocyte sedimentation rate
was noted only in two patients. All patients had normal
growth (body weight and body height) before diagnosis and
treatment according to the reference range for Taiwanese
children, except one patient below the age- and gender-
matched third percentile.
3.2. Endoscopic and histological findings
Endoscopic examination was performed in all patients, and
four of the 14 patients (28.6%) received microscopic
examination more than once because of nonspecific find-
ings in the beginning. One patient proceeded to intra-
operative enteroscopy because of suspected ileal bleeding
according to red blood cell bleeding scan. The endoscopic
examination revealed ulcer disease in four patients (4 of
14, 28.6%) and a negative finding in one patient (1 of 14,
7.1%) (Table 2). The other nine patients (9 of 14, 64.3%) had
nonspecific findings in their endoscopic examination,
including gastritis and duodenitis. The most common site
involved was the stomach, followed by duodenum and
colon (Figure 1). Multiple biopsy samples were taken at
various sites, including the esophagus, stomach, small
intestine, and colon, before the definite diagnosis was
made (Figure 2). The median number of biopsy specimen
taken from the gastrointestinal tract was 5.5 (range, 2e14).
3.3. Tissue eosinophilia versus nontissue
eosinophilia
We categorized our 14 patients into two groups, as shown in
Table 3. Nine out of 14 patients (64.3%) were grouped intodefinite eosinophilic gastroenteritis when they met the
criteria of tissue eosinophilia (>20 eosinophils per high
power field, 40 magnification level). In this group, four
did not have peripheral eosinophilia. The tissue eosino-
philia in five patients (five of nine, 55.6%) was found at
different sites of the gastrointestinal tract. The other five
patients were grouped into probable eosinophilic gastro-
enteritis because they only had peripheral eosinophilia
without tissue eosinophilia. We compared the age at diag-
nosis, duration of symptoms before diagnosis, biopsy
numbers, endoscopic finding, serum eosinophil count, and
relapse episodes between the two groups. Patients with
definite eosinophilic gastroenteritis had a lower age at
Figure 1 Colonoscopy in a 7-year-old boy reveals a large,
longitudinal, ovoid-shape ulcer covering half the circumfer-
ence at 25 cm above the anal verge. The lesion was hemor-
rhagic with irregular margin and whitish exudate coating. The
surrounding mucosa shows snake-skin appearance.
Pediatric eosinophilic gastroenteritis 275diagnosis (pZ 0.005). Patients with probable eosinophilic
gastroenteritis tended to have fewer biopsy samples than
those with definite eosinophilic gastroenteritis, but without
statistical significance (pZ 0.39). Among patients with
probable eosinophilic gastroenteritis, one had received 1-
week steroid therapy before endoscopic examination, and
all the remaining three had less than five biopsy specimens.
3.4. Treatment and prognosis
The treatment regimens included corticosteroid, mon-
telukast, and ketotifen (Table 4). Only one patient (1 of 14,
7%) received single corticosteroid, and four (4 of 14, 28.6%)
were treated with montelukast alone. One patient did not
receive any medication, but instead, received dietFigure 2 Histology shows chronic inflammation with signifi-
cant eosinophil infiltration in the stomach. (hematoxylin and
eosin stain, 400).elimination, including milk, egg, and peanut. Other
patients (8 of 14, 57.1%) had combination therapy with
corticosteroid, montelukast, and/or ketotifen. The dosages
of corticosteroid and montelukast were 1e2 mg/kg/d and
5 mg/d, respectively. The median follow-up duration was
11.6 months (0.5e79.5 months), and one patient was lost to
follow-up after 3.9 months of treatment. In 10 patients
with peripheral eosinophilia, the absolute eosinophil count
returned to normal in a mean duration of 191 days (5e1102
days). Seven patients (50%) had smooth treatment course
without any relapsing episode (Table 5). Three became
steroid dependent, and another three eventually tapered
off steroid therapy after several relapsing episodes. Patient
No. 10 had anemia as his initial manifestation and was
treated with steroid alone. His Hb level returned to normal
in 2 months, and steroid was successfully tapered off
steadily within 4 months. Among those eight patients
treated with the combination therapy, one patient (No. 7)
was lost to follow-up, and one (12.5%) (No. 4) was
successfully tapered off steroid within 9 days. The other
three patients (37.5%) (No. 1, 2, and 3) used steroid for
multiple episodes and eventually tapered off steroid after
a mean duration of 12.3 months. Three (37.5%) patients
(No. 6, 9, and 11) are still under steroid treatment. Four
patients (No. 5, 8, 12, and 13) treated with montelukast
alone had no relapse after the medication was applied. Two
of those patients had significant improvement in epigas-
tralgia, and the other two patients had a negative result in
stool occult blood after montelukast use.4. Discussion
Eosinophilic gastroenteritis is a rare disease in children,
characterized by eosinophil infiltration in the gastrointes-
tinal tract, resulting in abdominal symptoms. Diagnosis is
sometimes difficult and should be made with combination of
the pathology and clinical manifestations. Peripheral eosin-
ophilia is the initial clue for diagnosis but is not always
present in eosinophilic gastroenteritis.4, 14 In our study, one-
third of the patients did not have peripheral eosinophilia.
Interestingly, anemia with or without apparent gastrointes-
tinal bleeding was an important symptom, present in one-
third of our patients. Furthermore, half of our patients had
positive stool occult blood in the beginning, although they
may not have had gastrointestinal discomfort. The high
incidence of anemia in patients with eosinophilic gastroen-
teritis may be because of its recognizable features, such as
pale appearance or easy fatigue. Parents or clinicians will be
more alert to the symptoms and proceed to endoscopic
examinations. The actual incidence of eosinophilic gastro-
enteritis may be higher because those patients with minor
symptoms and without anemia may be underdiagnosed.
Once the eosinophilic gastroenteritis is suspected,
endoscopic examination should be arranged. The histolog-
ical evidence may be more reliable when making the
diagnosis, but negative histological findings cannot exclude
the possibility of eosinophilic gastroenteritis. Because
eosinophilic infiltration is usually patchy in distribution,
multiple sites of biopsy should be obtained to avoid missing
the diagnosis.17 In our patients, the biopsy specimen at
one site revealed normal appearance, whereas another
Table 3 Comparison of patients with or without tissue eosinophilia.
Group Age at
diagnosis (y)
Duration of
symptom before
diagnosis (mo)
Serum eosinophil
count (cells/mL)
Number
of biopsies
Ulcer
disease
Relapse
episodes
Group 1 (nZ 9)
Patients with tissue eosinophilia 5.9 11.0 2757 7.9 4 0.7
Group 2 (nZ 5)
Patients without tissue eosinophilia 13.2 6.0 3699 4.2 0 0.8
p* <0.005 0.72 0.48 0.35 0.15 0.42
* The p value was analyzed by Mann-Whitney U test.
276 F.-M. Tien et alspecimen at a different site had very significant tissue
eosinophilia. These findings implied that some patients
with suspected eosinophilic gastroenteritis should not be
excluded from this diagnosis even with normal histological
result. In our study, patients without tissue eosinophilia
seemed to have smaller biopsy numbers.
The real pathogenesis of eosinophilic gastroenteritis is
not fully understood, and heterogenous causes may be
responsible for this disease. The hypothesis of IgE-mediated
food allergy has been accepted for a long time.18 The
occasional coexistence of eosinophilic gastroenteritis and
atopic disorders, such as asthma, eczema, or allergic
rhinitis, may support this theory,19 but low proportion of
allergy history was also reported in other studies.4,20
Recently, the mechanism of cell-mediated hypersensi-
tivity was also presented by some authors.21,22 This may
explain why the result of allergen-specific IgE testing was
negative in most of the patients. In our study, only 28.6% of
patients had an atopic history, which made the history less
helpful in establishing the diagnosis. Only three patients in
our study were proved to have a specific food allergy by
allergen-specific IgE test. Patient No. 14 was allergic to
chocolate and eggs; thus, avoidance of these foods wasTable 4 Treatment and follow-up course in our patients.
Patient Treatment Duration of steroid use
1 CþM 7 mo
2 CþM 1 mo
3 CþM þ K 2 mo
4 CþM 9 d
5 M d
6 CþM þ K 2 mo
7 CþM Lost to follow-up
8 M  1 mo d
9 CþM Still under steroid
10 C 4 mo
11 CþM Still under steroid
12 M d
13 M d
14 Diet elimination d
CZ corticosteroid; KZ ketotifen; MZmontelukast; OB Z occult blorecommended. We did not give her medication except diet
elimination and followed up her Hb and stool occult blood.
Her Hb level gradually returned to normal, and stool occult
blood disappeared after 1 month. However, for those
patients with multiple food allergies, food avoidance is not
always practical. Talley et al4 reported that a past history
of allergy was found in 50% of the eosinophilic gastroen-
teritis patients in their study. Eighty percent of the patients
had a coexisting atopic disease, such as asthma, eczema, or
allergic rhinoconjunctivitis, in a world-wide-web-based
registry.23 Because atopic disease is highly prevalent in
Taiwan and about 5.6e8.1% of school children had a history
of asthma,24 we suspect that eosinophilic gastroenteritis
may be more prevalent than previously reported. A
prospective, large-scale study is mandated to actually
analyze the incidence of eosinophilic gastroenteritis.
Three of our patients were siblings (one elder brother,
patient No. 3, and two younger sister patients, No. 4 and 5)
coming from one family. All of them presented with epi-
gastralgia as initial manifestation, and two had an atopic
history. In one report, two siblings presenting with severe
iron-deficiency anemia and hypoalbuminemia were both
diagnosed with eosinophilic gastroenteritis.25 There hasDuration of
follow-up (mo)
Prognosis
47.1 4 relapse episodes
79.5 1 episode of relapse (1 y 9 mo
after steroid was discontinued)
27.0 3 mo after steroid discontinued
14.1 In remission
14.1 In remission
0.5 Still failure to thrive and under
TPN supplement
3.9 Loss of follow-up
11.3 In remission
4.4 Improved under steroid use
11.9 In remission
14.4 Occasional stool OB(þ)
2.5 In remission
2.0 In remission
1.0 In remission
od; TPN Z total parenteral nutrition.
Table 5 Outcomes of the 14 patients.
Outcome n Z 14
n (%)
No relapse 7 (50.0)
Successfully tapered off steroid
after several relapses (mean
duration, 12.3 mo)
3 (21.4)
Steroid dependent 3 (21.4)
Lost to follow-up 1 (7.2)
Pediatric eosinophilic gastroenteritis 277been no strong familial association of eosinophilic gastro-
enteritis reported previously, but a history of atopy may be
noted in these family members.23
There is no standard treatment for eosinophilic gastro-
enteritis, and corticosteroid remains the main regimen for
these patients. Other choices that have been used include
ketotifen,26,27 oral cromolyn,28 and a leukotriene antago-
nist.15,29 Immunotherapy, such as with suplatast tosilate, or
anti-interleukin 5 monoclonal antibodies,30, 31 has been
applied in some clinical trials, but the clinical effect was
limited. The treatment choice is variable according to
clinicians and depends on the severity and age of patients.
A previous study enrolling 17 children and infants diagnosed
with eosinophilic gastroenteritis displayed a benign and
treatable course compared with inflammatory bowel
disease.7 Only one out of 17 patients became steroid
dependent. In our study, 10 patients had a smooth treat-
ment course (10 of 14, 71.4%) and three patients (3 of 14,
21.4%) had difficulty in tapering steroid. Corticosteroid is
rapidly effective in symptom relief but carries the risk of
immunity suppression, increased susceptibility to infec-
tions, osteoporosis, growth failure, and mood or endocrine
disorders when used on a long-term basis.32e34 According to
previous studies, a leukotriene antagonist may be a good
alternative maintenance therapy for steroid-dependent
patients. In our study, three patients treated with a leuko-
triene antagonist alone had good outcome without relapse
during follow-up. This result gives us an additional option in
eosinophilic gastroenteritis, especially in steroid-
dependent patients. More randomized trials are required
to assess the long-term benefits and side effects of
a leukotriene antagonist in eosinophilic gastroenteritis.
In conclusion, eosinophilic gastroenteritis in children is
a rare disease, and its prevalence may be underestimated
in those patients not receiving endoscopic examinations
because of nonspecific symptoms or minor diseases. A high
index of suspicion is essential when the patient has
peripheral eosinophilia, positive stool occult blood, and
anemia. Endoscopic examination is necessary, and multiple
biopsy specimens should be taken. Steroid is the main
therapy in the acute stage, but montelukast may be a good
alternative therapy for minor diseases and as a long-term
maintenance treatment.References
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